Effect of the JAK1 Inhibitor, Upadacitinib, on Skin Barrier Repair of Eczema Elicited During Anti-Interleukin-17 Treatment for Psoriasis

Dermatitis. 2024 Sep-Oct;35(5):537-539. doi: 10.1089/derm.2023.0298. Epub 2023 Dec 29.

Authors

Shuhong Ye¹, Biao Yu², Jiawen Wu¹, Zining Xu¹, Bingyang Xu¹, Hong Sun³, Bin Zhao⁴

Affiliations

¹ Department of Dermatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China.
² Department of Dermatology, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
³ Department of Neurology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, China.
⁴ Department of Dermatology, Xi'an International Medical Center Hospital, Xi'an, China.

PMID: 38156810
DOI: 10.1089/derm.2023.0298

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use
Eczema* / drug therapy
Female
Heterocyclic Compounds, 3-Ring* / adverse effects
Heterocyclic Compounds, 3-Ring* / therapeutic use
Humans
Interleukin-17* / antagonists & inhibitors
Janus Kinase 1 / antagonists & inhibitors
Janus Kinase Inhibitors / therapeutic use
Psoriasis* / drug therapy

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring
Interleukin-17
Janus Kinase 1
Janus Kinase Inhibitors
Antibodies, Monoclonal, Humanized